Melendres, Marco B.
HRN: 24-09-39 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/11/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
11/11/2023
11/11/2023
IV
120mg
Q8
T/c Periorbital Cellulitis
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes